初级预防包括严格的感染控制。洗手和清洗共享的玩具可以减少病毒感染的传播。降低感染的传播:低质量的证据支持洗手能够降低毛细支气管炎的传播。 洗手是证据确凿的有效降低感染传播的措施。[7]Ralston SL, Lieberthal AS, Meissner HC, et al; American Academy of Pediatrics. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014 Nov;134(5):e1474-502.http://pediatrics.aappublications.org/content/134/5/e1474.longhttp://www.ncbi.nlm.nih.gov/pubmed/25349312?tool=bestpractice.com低质量的观察性(队列)研究或者受试者<200名且方法学存在缺陷的随机对照临床试验(RCT)。 美国儿科学会 (American Academy of Pediatrics, AAP) 建议,由于有 meta 分析表明烟草烟雾暴露和细支气管炎住院治疗的比值比升高,因此临床医生再询问婴儿照护者来评估儿童的细支气管炎时应注意烟草烟雾暴露的情况。[39]Jones LL, Hashim A, McKeever T, et al. Parental and household smoking and the increased risk of bronchitis, bronchiolitis and other lower respiratory infections in infancy: systematic review and meta-analysis. Respir Res. 2011 Jan 10;12:5.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022703/http://www.ncbi.nlm.nih.gov/pubmed/21219618?tool=bestpractice.com 目前,没有针对RSV有效的疫苗。 对于高危人群,可以考虑应用抗RSV单克隆抗体帕利珠单抗进行被动免疫治疗。[40]Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, American Academy of Pediatrics. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014 Aug;134(2):415-20. [Erratum in: Pediatrics. 2014 Dec;134(6):1221.]http://pediatrics.aappublications.org/content/134/2/415.fullhttp://www.ncbi.nlm.nih.gov/pubmed/25070315?tool=bestpractice.com 帕利珠单抗是一种人源化单克隆抗体,它能够与 RSV 的 F 蛋白结合,并且抑制病毒感染和复制。有关帕利珠单抗在早产儿和患有先天性心脏病的婴幼儿的随机对照临床试验已证明,应用帕利珠单抗可以显著降低住院风险。[41]Morris SK, Dzolganovski B, Beyene J, et al. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis. 2009 Jul 5;9:106.http://www.biomedcentral.com/1471-2334/9/106http://www.ncbi.nlm.nih.gov/pubmed/19575815?tool=bestpractice.com病死率和住院:有中等质量证据证明,与安慰剂相比,帕利珠单抗治疗慢性肺疾病(也称为支气管肺的发育不良)不能有效地降低儿童病死率。 然而证据表明,与安慰剂相比,帕利珠单抗能够更有效地减少RSV感染儿童的住院率。受试者<200名的随机对照临床试验(RCT)、受试者>200名且方法学存在缺陷的随机对照临床试验(RCT)、方法学存在缺陷的系统评价或者高质量的观察性(队列)研究。 因为这是一种被动免疫,必须每月应用帕利珠单抗。考虑到这项治疗的相关花费和耗费的人力,临床指南推荐在呼吸合胞病毒 (RSV) 感染的高发季节,仅给予高风险婴儿最多 5 个月(每月一次)的剂量。对于任何因 RSV 感染住院治疗且病情进展极迅速的儿童,应该停止预防治疗。
美国儿科学会 (American Academy of Pediatrics) 关于帕利珠单抗预防性治疗的推荐意见如下:[40]Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, American Academy of Pediatrics. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014 Aug;134(2):415-20. [Erratum in: Pediatrics. 2014 Dec;134(6):1221.]http://pediatrics.aappublications.org/content/134/2/415.fullhttp://www.ncbi.nlm.nih.gov/pubmed/25070315?tool=bestpractice.com[42]Bollani L, Baraldi E, Chirico G, et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr. 2015 Dec 15;41:97.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681171/http://www.ncbi.nlm.nih.gov/pubmed/26670908?tool=bestpractice.com[43]Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003 Oct;143(4):532-40.http://www.ncbi.nlm.nih.gov/pubmed/14571236?tool=bestpractice.com